Abstract
Background Reports indicate that COVID-19 may impact pancreatic function and increase type 2 diabetes (T2D) risk, although real-world COVID-19 impacts on HbA1c and T2D are unknown. We tested whether COVID-19 increased HbA1c, risk of T2D, or diabetic ketoacidosis (DKA).
Methods We compared pre- and post-COVID-19 HbA1c, and risk of developing T2D in a large real-world clinical cohort of 8,755 COVID-19(+) patients and a matched control cohort of 11,998 COVID-19(-) patients. We investigated if DKA risk was modified in COVID-19(+) patients with type 1 diabetes (T1D) (N=704) or T2D (N=22,904), or by race and sex.
Findings We observed a statistically significant, albeit clinically insignificant, HbA1c increase post-COVID-19 (all patients ΔHbA1c=0.06%, P<.001; with T2D ΔHbA1c=0.1%; P<.001), and no increase among COVID-19(-) patients (P>.05). COVID-19(+) patients were 40% more likely to be diagnosed with T2D compared to COVID-19(-) patients (P<.001) and 28% more likely to be diagnosed with T2D for the same HbA1c change as COVID-19(-) patients (P<.001). COVID-19(+) patients with T2D on insulin were 34% more likely to develop DKA compared to COVID-19(-) patients on insulin (P<.05), and COVID-19(+) Black patients with T2D displayed disproportionately increased DKA risk (HR:1.63, P=.007). There was no significant difference in DKA risk between COVID-19(+) and COVID-19(-) patients with T1D.
Interpretation DKA risk is increased in T2D patients on insulin and in Black patients with T2D after COVID-19 infection.T2D risk is greater in COVID-19(+) patients for the same HbA1c increase in COVID-19(-) patients, indicating that T2D risk attributed to COVID-19 may be due to increased recognition during COVID-19 management.
Funding No funding to report.
Competing Interest Statement
D.M.R., M.W.K., A.S., Ar.M. have received research funding from Novo Nordisk. K.M.P. has received research support from Bayer AG, Merck & Co., Inc,Novo Nordisk Inc, and Twinhealth, consulting honoraria from AstraZeneca, Bayer AG, Corcept Therapeutics Inc, Diasome, Eli Lilly and Company, Merck & Co., Inc,Novo Nordisk Inc, and Sanofi, speaker honoraria from AstraZeneca, Corcept Therapeutics Inc, Merck & Co., Inc and Novo Nordisk Inc in the past 12 months. A.M.H. has received funding from the Agency for Healthcare Research and Quality grant # K08HS024128 and reports grants from NHLBI, grants from NIH-National Human Genome Research Institute, grants from Novo Nordisk Inc, grants from Merck & Co., Inc, and grants from Boehringer Ingelheim Pharmaceuticals Inc, outside the submitted work. D.M.R., K.M.P., and Ar.M. have intellectual property related to treatment decision making in the context of type 2 diabetes. No other potential conflicts of interest relevant to this article were reported.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Cleveland Clinic gave ethical approval for this work that used the Cleveland Clinic's approved COVID-19 registry.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data related to this manuscript will be made available upon request in adherence with transparency conventions in medical research and through requests to the corresponding author.
